Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine

NCT05201352 is registered in ClinicalTrials.gov with Centre Georges Francois Leclerc as lead sponsor.

NCT NCT05201352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
Lead sponsor
Centre Georges Francois Leclerc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 13, 2022
Completion date
October 13, 2026
Enrollment
160 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer